Nasus Pharma Ltd (NSRX) income statement
NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
$2.29−0.26 (-10.20%)
Close on Nov 20, 2026Market cap $20.65MP/E –Yield –
Nasus Pharma Ltd financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $20.65MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Margins | ||||
| Operating margin | -0.40% | – | – | – |
| Net profit margin | -0.47% | – | – | – |
| Free cash flow margin | -0.40% | – | – | – |
| Returns on capital | ||||
| Return on equity | -2,637.8% | -43.7% | -31.9% | – |
| Return on assets | -204.7% | -213.7% | – | – |
| Return on tangible assets | -204.7% | -213.7% | – | – |
| Return on capital employed | 2,643.7% | 33.6% | – | – |
| NOPAT | -$3.87M | -$851.62K | -$906.13K | – |
| Cash flow quality | ||||
| OCF / Sales | -0.40% | – | – | – |
| OCF / Net income | 0.84 | 0.43 | 0.98 | – |
| FCF / OCF | 100.3% | – | – | – |
| FCF / Net income | 0.84 | – | – | – |
| Unlevered free cash flow | -$4.99M | – | – | – |
| Levered free cash flow | -$4.93M | – | – | – |
| Efficiency | ||||
| Asset turnover | 431.74 | – | – | – |
| Fixed asset turnover | 88,214.29 | – | – | – |
| CapEx to revenue | 0.00% | – | – | – |
| CapEx to OCF | -0.28% | – | – | – |
| Liquidity | ||||
| Current ratio | 2.24 | 0.12 | – | – |
| Quick ratio | 2.24 | 0.12 | – | – |
| Cash ratio | 0.57 | 0.07 | – | – |
| Working capital | $2.69M | -$3.47M | – | – |
| Net current asset value | $2.62M | -$3.47M | – | – |
| Leverage | ||||
| Assets to equity | 1.81 | -0.22 | – | – |
| Interest coverage | ||||
| EBIT / Interest expense | -62.87 | -37.17 | -23.41 | – |
| Per share | ||||
| Revenue per share | 136.99 | – | – | – |
| EPS (basic) | -0.72 | -0.22 | -0.15 | – |
| EPS (diluted) | -0.72 | -0.22 | -0.20 | – |
| Book value per share | 0.31 | -0.44 | -0.54 | – |
| Tangible book value per share | 0.31 | -0.44 | -0.54 | – |
| Cash per share | 0.14 | 0.04 | 0.03 | – |
| Operating cash flow per share | -0.55 | -0.09 | -0.15 | – |
| Free cash flow per share | -0.55 | – | – | – |
| CapEx per share | 0.0016 | – | – | – |
| Valuation at period end | ||||
| Market cap | $67.37M | – | – | – |
| Enterprise value | $67.17M | – | – | – |
| P/S | 0.1x | – | – | – |
| P/B | 24.3x | – | – | – |
| P/TBV | 24.3x | – | – | – |
| P/OCF | -13.7x | – | – | – |
| EV/Sales | 0.1x | – | – | – |
| EV/OCF | -13.7x | – | – | – |
| Earnings yield | -8.7% | – | – | – |
| FCF yield | -7.3% | – | – | – |
| Cost structure | ||||
| R&D to revenue | 0.18% | – | – | – |
| Stock-based comp to revenue | 0.04% | – | – | – |
| Growth | ||||
| EBIT 1Y growth | -354.9% | 6.0% | – | – |
| Net income 1Y growth | -282.2% | -45.8% | – | – |
| Diluted EPS 1Y growth | -227.3% | -10.0% | – | – |
| Operating cash flow 1Y growth | -639.5% | 35.4% | – | – |
| Total assets 1Y growth | 597.9% | – | – | – |
| Total equity 1Y growth | 186.2% | 15.4% | -36.3% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.